厂内车辆运货时不能超载，货物应堆放牢固、均匀，装货后的高度离地面不得超过（）米。A．

男性，60岁，双下肢无力7年。患者7年前无明显诱因出现双下肢疲乏，呈进行性加重，伴步态不稳，如"脚下踩棉花感"。时作颈项板滞，双上肢沉重、无力。查体：颈椎生理弧度变直，04～6棘旁压痛，双下肢肌张力增高，膝、踝反射亢进，Hoffmann（+），踝阵挛（+）。X光片示：颈椎退行性变。

如对该患者行牵引治疗，牵引的重量是（）

A.1／3体重

B.1／2体重

C.1／10体重或稍超过

D.1／15体重或稍超过

E.1／20体重或稍超过

F.1／25体重或稍超过

(1)暴雨倾盆(2)紧急动员(3)战胜洪水(4)冲垮大堤(5)抗灾抢险正确选项为( )

A．1—2—4—3—5

B．1—4—2—5—3

C．5—3—4—2—1

D．4—1—2—3—5

不合格的分项工程，经加固、补强、返工或整修后，当重新评定的评分值大于85分时，该分项工程可评为优良工程。( )

Animal studies are under way, human trial protocols are taking shape and drug makers are on alert. All the international health community needs now is a human vaccine for the bird flu pandemic sweeping a cluster of Asian countries.

The race for a vaccine began after the first human case emerged in Hong Kong in 1997. Backed by the World Health Organization (WHO), three research teams in the US and UK are trying to create a seed virus for a new vaccine. Their task is formidable, but researchers remain optimistic." There are obstacles, but most of the obstacles have been treated sensibly," says Richard Webby, a virologist at St. Jude Children’s Research Hospital in Memphis, Tennessee.

The biggest challenge is likely to be the rapidly mutating virus. Candidate vaccines produced last year against the H5N1 virus are ineffective against this year’s strain. Scientists will have to constantly monitor the changes and try to tailor the vaccine as the virus mutates. They can’t wait to see which one comes next.

The urgency stems from fears that I-ISN1 will combine with a human flu virus, creating a pathogen(病原体) that could be transmitted from person to person. But if people have no immunity to the virus, the strain may not mutate as rapidly in people as it does in birds.

To quickly generate the vaccine, researchers are using reverse genetics, which allows them to skip the long process of searching through reassorted viruses for the correct genetic combination. Instead, scientists clone sequences for hemagglutinin(红血球凝聚素) and neuraminidase(神经氨酸苷酶), the two key proteins in the virus. The sequences are then combined with human influenza genes to create a customized reference strain.

Because products developed with reverse genetics have never been tested in humans, the candidate vaccines will first have to clear regulatory review. In anticipation, the US Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) are both preparing pandemic response plans. The EMEA has produced a fist-track licensing program, an industry task force and detailed guidance for potential applicants.

In Europe, a reassortant influenza virus -- but not the inactivated vaccine -- produced by reverse genetics would be considered a genetically modified organism, and manufacturers would need approval from their national or local safety authorities. The WHO has prepared a preliminary biosafety risk assessment of pilot-lot vaccine, which could help speed up the review.

A preliminary version of their protocol calls for several hundred subjects, beginning with a group of young adults and gradually expanding to include those most susceptible to the flu -- children and the elderly." If we had product," says Lambert," it would probably be a couple of months at the earliest before we have early data in healthy adults.

The vaccine generated by reverse genetics is required to review in that （）

A. it has p side effect to the elderly

B. it may turn ineffective in a short period

C. it is useless in preventing the virus

D. it hasn’t been tested in humans

哪些因素影响了汽包水位的变化？